Gsa Capital Partners LLP Supernus Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

$1.43 Billion
Q2 2025

A detailed history of Gsa Capital Partners LLP transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Gsa Capital Partners LLP holds 35,283 shares of SUPN stock, worth $1.16 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares

35,283

Previous 90,538 61.03%

Holding current value

$1.16 Million

Previous $2.97 Million 62.5%

% of portfolio

0.08%

Previous 0.27%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Jul 22, 2025	SELL	$30.29 - $33.43 $1.67 Million - $1.85 Million	-55,255 Reduced 61.03%	35,283 $1.11 Million
Q1 2025 May 08, 2025	BUY	$31.17 - $40.0 $2.23 Million - $2.86 Million	71,478 Added 375.02%	90,538 $2.97 Million
Q4 2024 Feb 07, 2025	SELL	$31.89 - $37.83 $1.4 Million - $1.66 Million	-43,771 Reduced 69.66%	19,060 $689,000
Q3 2024 Nov 05, 2024	BUY	$25.77 - $35.16 $1.11 Million - $1.51 Million	43,086 Added 218.21%	62,831 $1.96 Million
Q2 2024 Aug 15, 2024	BUY	$25.99 - $33.85 $323,601 - $421,466	12,451 Added 170.7%	19,745 $528,000
Q1 2024 May 03, 2024	SELL	$27.11 - $35.17 $27,950 - $36,260	-1,031 Reduced 12.38%	7,294 $248,000
Q4 2023 Feb 16, 2024	BUY	$22.72 - $29.68 $23,583 - $30,807	1,038 Added 14.24%	8,325 $240,000
Q3 2023 Nov 15, 2023	BUY	$27.57 - $32.91 $200,902 - $239,815	7,287 New	7,287 $200,000
Q4 2022 Feb 13, 2023	BUY	$31.09 - $37.88 $509,689 - $621,004	16,394 New	16,394 $585,000
Q2 2022 Aug 09, 2022	SELL	$25.33 - $34.25 $253,882 - $343,287	-10,023 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$28.51 - $32.9 $285,755 - $329,756	10,023 New	10,023 $324,000
Q1 2020 May 12, 2020	SELL	$14.45 - $24.69 $620,266 - $1.06 Million	-42,925 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$19.93 - $29.13 $658,467 - $962,426	33,039 Added 334.2%	42,925 $1.02 Million
Q3 2019 Nov 12, 2019	BUY	$25.47 - $33.37 $251,796 - $329,895	9,886 New	9,886 $272,000
Q1 2019 May 15, 2019	SELL	$32.77 - $41.99 $285,099 - $365,313	-8,700 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$30.84 - $49.51 $268,308 - $430,737	8,700 New	8,700 $289,000
Q3 2018 Nov 13, 2018	SELL	$42.7 - $56.55 $1.53 Million - $2.02 Million	-35,777 Closed	0 $0
Q2 2018 Aug 09, 2018	SELL	$44.1 - $59.85 $1.16 Million - $1.58 Million	-26,357 Reduced 42.42%	35,777 $2.14 Million
Q1 2018 May 11, 2018	SELL	$37.15 - $46.9 $185,750 - $234,500	-5,000 Reduced 7.45%	62,134 $2.85 Million
Q4 2017 Feb 14, 2018	BUY	$36.4 - $42.6 $946,400 - $1.11 Million	26,000 Added 63.21%	67,134 $2.68 Million
Q3 2017 Nov 20, 2017	BUY	$36.75 - $49.65 $1.51 Million - $2.04 Million	41,134	41,134 $1.65 Million

Others Institutions Holding SUPN

# of Institutions

303

Shares Held

60.7M

Call Options Held

8.8K

Put Options Held

6.3K

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.76B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

News

Stay updated on Gsa Capital Partners LLP with notifications on news.

Account

Gsa Capital Partners LLP Supernus Pharmaceuticals, Inc. Transaction History